Skip to main content
Fig. 1 | Alzheimer's Research & Therapy

Fig. 1

From: Evaluation of cerebrospinal fluid levels of synaptic vesicle protein, VAMP-2, across the sporadic Alzheimer’s disease continuum

Fig. 1

Novel VAMP-2 immunoassay features. A Schematic overview of VAMP-2 protein sequence aligned with the protein fragment (red) that is recognized by the VAMP-2 immunoassay consisting of mAbs RD087 and D601A. VAMP-2 protein domains are indicated and assigned with different colours. Highlighted in green is the MRM peptide sequence used by Lleó et al. (2019) [13] to quantify VAMP-2 in CSF of subjects with sporadic Alzheimer’s disease. Created with BioRender.com. B Clinical frequency distribution of CSF VAMP-2 levels in patients from the Alzheimer’s continuum (n = 152) and cognitively healthy controls (n = 62) combined with the assays’ calibration curves (red) from five Simoa runs. The CSF concentrations of three QC samples used in the cohort are highlighted in green and the LLOQ is marked with a dotted line. VAMP-2, vesicle-associated membrane protein-2; mAbs, monoclonal antibodies; MRM, multiple reaction monitoring; LLOQ, lower limit of quantification; QC, quality control

Back to article page

Alzheimer's Research & Therapy

ISSN: 1758-9193